FDA rejects MAPS/Lykos MDMA therapy for PTSD

On Aug 9th the FDA rejected the new drug application by Lykos (formerly MAPS PBC) for MDMA-assisted therapy for PTSD. This is disappointing news for those of us who were excited about the promising study results and eager to add MDMA-assisted therapy to the menu of treatment options for those suffering with PTSD. We discuss what appears to have influenced the FDA’s decision, the possible path forward for Lykos, how this ruling affects other companies trying to bring different psychedelic medicines to market, and much more.

Learn more about our podcast at https://numinus.com/podcast/
Learn more about psychedelic therapy training opportunities at https://numinus.com/training/
Learn more about our clinical trials at https://www.numinus.com/clinical-trials
Learn more about Numinus at https://numinus.com/

Email us at [email protected]

Follow us on Instagram:
  / drstevethayer  
  / innerspacedoctor  
  / numinushealth  

00:00 FDA's Decision and Its Implications
13:24 Criticisms and Biases in MDMA Therapy Studies
18:02 FDA's Decision and Its Implications
21:48 Current PTSD Treatments and Their Limitations